Compugen Ltd.

Compugen Ltd. is a clinical-stage predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange, and its market cap is about $367.4M as of May 2023. Compugen was established as a computational drug discovery service provider in 1993 and has since evolved into a leader in the field of immuno-oncology.

Compugen's vision is to use its predictive computational platform to discover untapped drug targets and extend the reach of cancer immunotherapies to new patient populations. Compugen's platform leverages the power of artificial intelligence and big data to identify novel drug candidates that modulate the immune system and enhance anti-tumor responses.

Compugen's pipeline consists of several potentially first-in-class therapeutic antibodies targeting novel pathways that are currently being evaluated in multiple clinical trials. One of Compugen's most advanced programs is COM701, a monoclonal antibody that blocks PVRIG, a novel immune checkpoint that Compugen discovered and validated. COM701 is being tested as a monotherapy and in combination with other immune checkpoints in patients with advanced solid tumors.

Compugen has also received several awards and recognitions for its innovation and excellence in the field of drug discovery. In 2020, Compugen was named one of the world's most innovative companies by Fast Company magazine. In 2019, Compugen received the prestigious SCRIP Award for Best Licensing Deal for its collaboration with AstraZeneca. In 2018, Compugen was selected as one of the Fierce 15 biotech companies by FierceBiotech.

Foundation: 1993

Headquarters: Holon, Israel

Website: https://www.cgen.com/